Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)
Key facts
- Where
- Dresden, Essen, Heidelberg, Mannheim, and Wölfersheim, GermanySee the 5 sites
Where in Germany
- Technical University DresdenDresden, GermanyTaking people
- University Hospital EssenEssen, GermanyNot yet recruiting
- NCT HeidelbergHeidelberg, GermanyTaking people
- Sarcoma Center MannheimMannheim, GermanyTaking people
- Deutsche Sarkom-StiftungWölfersheim, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Technische Universität Dresden
- Trial code
- NCT07148193
- Record updated
- 8 December 2025
- Original description
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.Read full original descriptionShow less
Understanding Long-Term Sarcoma Survivorship: Risk Profiles, Outcomes and Unmet Needs - A Joint Project of Research, Sarcoma Centres and Patient Experts (PROSa+)
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Inclusion: Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST; At least 5 years since initial sarcoma diagnosis; With or without active disease; Age ≥18 years at the time of study participation.
Exclusion: Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia); Diagnosis of Desmoid tumors.